On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for information (RFI) related to clinical studies of ibogaine. In the notice, FDA outlines a potential early-stage ibogaine clinical trial design, which it says is consistent with its final guidance for clinical investigations of psychedelics…
